Oliver Gautschi - Concepedia

Author

Oliver Gautschi

Also Known As

Gautschi, Oliver, Kawahara, Masaaki, O Gautschi, O P Gautschi, O. Gautschi, O. P. Gautschi, O.P. Gautschi, Oliver Gautschi, Oliver P Gautschi, Oliver P. Gautschi

478

Publications

17K

Citations

H-Index

129

Concepts

All Affiliations

Kantonsspital St. Gallen University of Lucerne University Hospital of Zurich University of Bern University Hospital of Bern

About

Oliver Gautschi is an author at Kantonsspital St. Gallen specializing in medicine, oncology, and lung cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	40	99	7.3K
2	Health Sciences	20	28	1.7K
3	Business	1	1	36
4	Education	1	1	68
5	Public Health	1	1	32

Oliver Gautschi

162

Publications

14.6K

Citations

H-Index

Page 1

	Year	Citations
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry J. Mazieres, Alexander Drilon, Amélie Lusque, Annals of Oncology Advanced Lung CancerCancer ImmunosurveillanceMedicineImmune Checkpoint InhibitorsImmunology	2019	1.3K
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer Alexander Drilon, Geoffrey R. Oxnard, Daniel Shao-Weng Tan, New England Journal of Medicine	2020	810
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers Lori J. Wirth, Eric J. Sherman, Bruce Robinson, New England Journal of Medicine	2020	731
Lung Cancer That Harbors an <i>HER2</i> Mutation: Epidemiologic Characteristics and Therapeutic Perspectives Julien Mazières, Solange Peters, Benoît Lepage, Journal of Clinical Oncology	2013	651
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial Alice T. Shaw, Tae Min Kim, Lucio Crinò, The Lancet Oncology MedicineCeritinib Versus ChemotherapyPathologyBronchial NeoplasmCancer Treatment	2017	574
Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients Myriam Delaunay, J. Cadranel, Amélie Lusque, European Respiratory Journal	2017	416
Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial Miklos Pless, Roger Stupp, Hans-Beat Ris, The Lancet MedicineBronchial NeoplasmInduction ChemoradiationCancer TreatmentOncology	2015	380
Targeting RET in Patients With <i>RET</i>-Rearranged Lung Cancers: Results From the Global, Multicenter <i>RET</i> Registry Oliver Gautschi, Julie Milia, Thomas Filleron, Journal of Clinical Oncology	2017	349
Crizotinib Therapy for Advanced Lung Adenocarcinoma and a <i>ROS1</i> Rearrangement: Results From the EUROS1 Cohort Julien Mazières, Gérard Zalcman, Lucio Crinò, Journal of Clinical Oncology	2015	348
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort Julien Mazières, Fabrice Barlési, Thomas Filleron, Annals of Oncology MedicinePathologyHer2-targeted DrugsBronchial NeoplasmEuropean Euher2 Cohort	2015	320

Page 1